Oral ingestion of Streptococcus thermophilus does not affect mucositis severity or tumor progression in the tumor-bearing rat

Cancer Biology and Therapy

Volumn 12, Issue 2, 2011, Pages 131-138

  Tooley, Katie L ^a,b   Howarth, Gordon S ^a,b   Lymn, Kerry A ^a,b   Lawrence, Andrew ^c   Butler, Ross N ^a,b  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c WOMEN S AND CHILDREN S HOSPITAL   (Australia)

Author keywords

DAMA; Methotrexate; Mucositis; S. thermophilus; Small intestine; Sucrose breath test; Tumor model

Indexed keywords

METHOTREXATE; MYELOPEROXIDASE; PROBIOTIC AGENT; SUCRASE; TH 4; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; BREAST ADENOCARCINOMA; BREATH ANALYSIS; CANCER GROWTH; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; ENZYME ACTIVITY; FEMALE; HISTOPATHOLOGY; INTESTINE FUNCTION; INTESTINE INJURY; MUCOSA INFLAMMATION; NONHUMAN; RAT; STREPTOCOCCUS THERMOPHILUS; SUCROSE C 13 BREATH TEST;

ADENOCARCINOMA; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; EATING; FEMALE; INTESTINAL DISEASES; INTESTINE, SMALL; MAMMARY NEOPLASMS, EXPERIMENTAL; METHOTREXATE; MUCOSITIS; PROBIOTICS; RATS; RATS, INBRED STRAINS; STREPTOCOCCUS THERMOPHILUS;

EID: 79960417569     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.12.2.15720     Document Type: Article

References (44)

1. Mitchell EP, Schein PS. Gastrointestinal toxicity of chemotherapeutic agents. Semin Oncol 1982; 9:52-64. (Pubitemid 12116286)
2. Ijiri K, Potten CS. Response of intestinal cells of differing topographical and hierarchical status to ten cytotoxic drugs and five sources of radiation. Br J Cancer 1983; 47:175-85. (Pubitemid 13185479)
3. Xian CJ, Couper R, Howarth GS, Read LC, Kallincos NS. Increased expression of HGF and c-met in rat small intestine during recovery from methotrexateinduced mucositis. Br J Cancer 2000; 82:945-52. (Pubitemid 30085250)
4. Keefe DM, Cummins AG, Dale BM, Kotasek D, Robb TA, Sage RE. Effect of high-dose chemotherapy on intestinal permeability in humans. Clin Sci 1997; 92:385-9.
5. Ikuno N, Soda H, Watanabe M, Oka M. Irinotecan (CTP-11) and characteristic mucosal changes in the mouse ileum and cecum. J Natl Cancer Inst 1995; 87:1876-83.
6. Keefe DM. Intestinal mucositis: mechanisms and management. Curr Opin Oncol 2007; 19:323-7. (Pubitemid 46883520)
7. Sonis ST, Elting LS, Keefe DM, Peterson DE, Schubert M, Hauer-Jensen M, et al. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology and consequences for patients. Cancer 2004; 100:1995-2025. (Pubitemid 38528741)
8. Keefe DM, Brealey J, Goland GJ, Cummins AG. Chemotherpay for cancer causes apoptosis that precedes hypoplasia in crypts of the small intestine in humans. Gut 2000; 47:632-7.
9. Taminiau JA, Gall DA, Hamilton JR. Response of the rat small-intestine epithelium to methotrexate. Gut 1980; 21:486-92. (Pubitemid 10059409)
10. Howarth GS, Tooley KL, Davidson GP, Butler RN. A non-invasive method for detection of intestinal mucositis induced by different classes of chemotherapy drugs in the rat. Cancer Biol Ther 2006; 5:1189-95. (Pubitemid 44772236)
11. Tooley KL, Howarth GS, Lymn K, Lawrence A, Butler RN. Oral ingestion of Streptococcus thermophilus diminishes severity of small intestinal mucositis in methotrexate treated rats. Cancer Biol Therap 2006; 5:593-600. (Pubitemid 44024712)
12. Torres DM, Tooley KL, Butler RN, Smith CL, Geier MS, Howarth GS. Lyprinol(trade mark) only partially improves indicators of small intestinal integrity in a rat model of 5-fluorouracil-induced mucositis. Cancer Biol Ther 2007; 7:295-302. (Pubitemid 351590440)
13. Keefe DM, Rassias G, O'Neil L, Gibson RJ. Severe mucositis: how can nutrition help? Curr Opin Clin Nutr Metab Care 2007; 10:627-31.
14. Isolauri E. Probiotics in human disease. Am J Clin Nutr 2001; 73:1142-6.
15. Mombelli B, Gismondo MR. The use of probiotics in medical practice. Int J Antimicrob Agents 2000; 16:531-6.
16. Isolauri E, Kirjavainen PV, Salminen S. Probiotics: a role in the treatment of intestinal infection and inflammation? Gut 2002; 50:54-9.
17. Forestier C, De Champs C, Vatoux C, Joly B. Probiotic activities of Lactobacillus casei rhamnosus: in vitro adherence to intestinal cells and antimicrobial properties. Res Microbiol 2001; 152:167-73. (Pubitemid 32222962)
18. Resta-Lenert S, Barrett KE. Live probiotics protect intestinal epithelial cells from the effects of infection with enteroinvasive Esherichia coli (EIEC). Gut 2003; 52:988-97. (Pubitemid 36765291)
19. Thibault J, Aubert-Jacquin C, Goulet O. Effects of long-term consumption of a fermented infant formula (with Bifidobacterium breve c50 and Streptococcus thermophilus 065) on acute diarrhea in healthy infants. J Pediatr Gastroenterol Nutr 2004; 39:147-52.
20. Saavedra JM, Bauman NA, Oung I, Perman JA, Yolken RH. Feeding of Bifidobacterium bifidum and Streptococcus thermophilus to infants in hospital for prevention of diarrhoea and shedding of rotavirus. Lancet 1994; 344:1046-9. (Pubitemid 24310035)
21. Shibolet O, Karmeli F, Eliakim R, Swennen E, Brigidi P, Gionchetti P, et al. Variable response to probiotics in two models of experimental colitis in rats. Inflamm Bowel Dis 2002; 8:399-406. (Pubitemid 36411026)
22. Venturi A, Gionchetti P, Rizzello E, Johansson R, Zucconi E, Brigidi P, et al. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther 1999; 13:1103-8. (Pubitemid 29374113)
23. Bowen JM, Stringer AM, Gibson RJ, Yeoh AS, Hannam S, Keefe DM. VSL#3 probiotic treatment reduces chemotherapy-induced diarrhea and weight loss. Cancer Biol Ther 2007; 6:1449-54. (Pubitemid 351590357)
24. Southcott E, Tooley KL, Howarth GS, Davidson GP, Butler RN. Yogurts containing probiotics reduce disruption of the small intestinal barrier in methotrexatetreated rats. Dig Dis Sci 2008; 53:1837-41.
25. Crittenden RG, Martinez NR, Playne MJ. Synthesis and utilisation of folate by yoghurt starter cultures and probiotic bacteria. Int J Food Microbiol 2002; 80:217-22. (Pubitemid 35292672)
26. Gibson RJ, Keefe DM, Thompson FM, Clarke JM, Goland GJ, Cummins AG. Effect of Interleukin-11 on ameliorating intestinal damage after methotrexate treatment of breast cancer in rats. Dig Dis Sci 2002; 47:2751-7. (Pubitemid 35471617)
27. Clarke JM, Pelton NS, Bajka BH, Howarth GS, Read LC, Butler RN. Use of the sucrose breath test to assess chemotherapy-induced mucositis in the rat. Cancer Biol Ther 2006; 5:34-8. (Pubitemid 43234975)
28. Rofe AM, Bais R, Conyers RA. Ketone-body metabolism in tumour-bearing rats. Biochem J 1986; 233:485-91. (Pubitemid 16169497)
29. Gibson RJ, Bowen JM, Inglis MR, Cummins AG, Keefe DM. Irinotecan causes severe small intestinal damage, as well as colonic damage, in the rat with implanted breast cancer. J Gastroenterol Hepatol 2003; 18:1095-100. (Pubitemid 37175953)
30. Gibson RJ, Keefe DM, Clarke JM, Regester GO, Thompson FM, Goland GJ, et al. The effect of keratinocyte growth factor on tumour growth and small intestinal mucositis after chemotherapy in the rat with breast cancer. Cancer Chemother Pharmacol 2002; 50:53-8. (Pubitemid 34743996)
31. Gibson RJ, Bowen JM, Alvarez E, Finnie J, Keefe DM. Establishment of a single-dose irinotecan model of gastrointestinal mucositis. Chemotherapy 2007; 53:360-9. (Pubitemid 47415438)
32. Broder S, Waldmann TA. The suppressor cell network in cancer (first of two parts). N Engl J Med 1978; 299:1281-4. (Pubitemid 9115797)
33. thor Straten P, Becker JC, Guldberg P, Zeuthen J. In situ T cells in melanoma. Cancer. Immunol Immunother 1999; 48:386-95.
34. Van der Wilt CL, Braakhuis BJ, Pinedo HM, De Jong M, Smid K, Peters GJ. Addition of leucovorin in modulation of 5-fluorouracil with methotrexate: potentiating or reversing effect? Int J Cancer 1995; 61:672-8.
35. Diddens H, Teufel T, Niethammer D. High-dose methotrexate with leucovorin rescue: in vitro investigations on human osteosarcoma cell lines. Cancer Chemother Pharmacol 1987; 20:128-32. (Pubitemid 17151999)
36. Sepehr E, Peace RW, Storey KB, Jee P, Lampi BJ, Brooks SJ. Folate derived from cecal bacterial fermentation does not increase liver folate stores in 28-d folate-depleted male sprague dawley rats. J Nutr 2003; 133:1347-54. (Pubitemid 36548705)
37. Rofe AM, Bourgeois CS, Washington JM, Philcox JC, Coyle P. Metabolic consequences of methotrexate therapy in tumour-bearing rats. Immunol Cell Biol 1994; 72:43-8. (Pubitemid 24068046)
38. 14C]glucose uptake in normal and neoplastic tissues in the rat. Biochem J 1988; 253:603-6.
39. Gibson RJ, Bowen JM, Keefe DM. Palifermin reduces diarrhea and increases survival following irinotecan treatment in tumor-bearing DA rats. Int J Cancer 2005; 116:464-70. (Pubitemid 40993345)
40. Logan RM, Gibson RJ, Bowen JM, Stringer AM, Sonis ST, Keefe DM. Characterization of mucosal changes in the alimentary tract following administration of irinotecan: implications for the pathobiology of mucositis. Cancer Chemother Pharmacol 2008; 62:33-41. (Pubitemid 351537842)
41. Logan RM, Stringer AM, Bowen JM, Gibson RJ, Sonis ST, Keefe DM. Serum levels of NFkappaB and proinflammatory cytokines following administration of mucotoxic drugs. Cancer Biol Ther 2008; 7:1139-45.
42. Tomas FM, Knowles SE, Owens PC, Read LC, Chandler CS, Gargosky SE, et al. Effects of full-length and truncated insulin-like growth factor-I on nitrogen balance and muscle protein metabolism in nitrogenrestricted rats. J Endocrinol 1991; 128:97-105.
43. Howarth GS, Cool JC, Bourne AJ, Ballard FJ, Read LC. Insulin-like growth factor-I (IGF-I) simulates regrowth of the damaged intestine in rats, when administered following, but not concurrent with, methotrexate. Growth Factors 1998; 15:279-92. (Pubitemid 28404369)
44. Howarth GS, Francis GL, Cool LC, Xu X, Byard RW, Read LC. Milk growth factors enriched from cheese whey ameliorate intestinal damage by methotrexate when administered orally to rats. J Nutr 1996; 126:2519-30. (Pubitemid 26339666)